
WHO members adopt global pandemic accord, but US absence casts doubts
GENEVA: Members of the World Health Organization adopted an agreement on Tuesday intended to improve preparedness for future pandemics following the disjointed global response to COVID-19, but the absence of the U.S. cast doubt on the treaty's effectiveness.
After three years of negotiations, the legally binding pact was adopted by the World Health Assembly in Geneva. WHO member countries welcomed its passing with applause.
The pact was touted as a victory for members of the global health agency at a time when multilateral organisations like the WHO have been battered by sharp cuts in U.S. foreign funding.
'The agreement is a victory for public health, science and multilateral action. It will ensure we, collectively, can better protect the world from future pandemic threats,' said WHO Director-General Tedros Adhanom Ghebreyesus.
The pact aims to ensure that drugs, therapeutics and vaccines are globally accessible when the next pandemic hits. It requires participating manufacturers to allocate a target of 20% of their vaccines, medicines and tests to the WHO during a pandemic to ensure poorer countries have access.
However, U.S. negotiators left discussions about the accord after President Donald Trump began a 12-month process of withdrawing the U.S. - by far the WHO's largest financial backer - from the agency when he took office in January.
Given this, the U.S., which poured billions of dollars into vaccine development during the COVID pandemic, would not be bound by the pact. And WHO member states would not face penalties if they failed to implement it.
U.S. Health and Human Services Secretary Robert F. Kennedy Jr. slammed the World Health Organization in a video address to the Assembly, saying it had failed to learn from the lessons of the pandemic with the new agreement.
'It has doubled down with the pandemic agreement which will lock in all of the dysfunction of the WHO pandemic response... We're not going to participate in that,' he said.
LATE CHALLENGE
The deal was reached after Slovakia called for a vote on Monday, as its COVID-19 vaccine-sceptic prime minister demanded that his country challenge the adoption of the agreement.
One hundred and twenty-four countries voted in favour, no countries voted against, while 11 countries, including Poland, Israel, Italy, Russia, Slovakia and Iran, abstained.
Some health experts welcomed the treaty as a step towards greater fairness in global health after poorer nations were left short of vaccines and diagnostics during the COVID-19 pandemic.
'It contains critical provisions, especially in research and development, that — if implemented — could shift the global pandemic response toward greater equity,' Michelle Childs, Policy Advocacy Director at Drugs for Neglected Diseases initiative, told Reuters.
Others said the agreement did not meet initial ambitions and that, without strong implementation frameworks, it risked falling short in a future pandemic.
'It is an empty shell... It's difficult to say that it's a treaty with firm obligation where there is a strong commitment... It's a good starting point. But it will have to be developed,' said Gian Luca Burci, an academic adviser at the Global Health Centre at the Geneva Graduate Institute, an independent research and education organisation.
Helen Clark the co-Chair of The Independent Panel for Pandemic Preparedness and Response, described the accord as a foundation to build from.
'Many gaps remain in finance, equitable access to medical countermeasures and in understanding evolving risks,' she added.
The pact will not go into effect until an annex on sharing of pathogenic information is agreed. Negotiations on this would start in July with the aim of delivering the annex to the World Health Assembly for adoption, WHO said. A Western diplomatic source suggested it may take up to two years to be agreed.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


The Star
4 hours ago
- The Star
Kennedy's firing of independent CDC advisers undermines vaccine confidence, experts say
A woman receives a booster dose of the COVID-19 vaccine at the Police hospital in Bangkok, Thailand, January 5, 2023. REUTERS/Athit Perawongmetha/File Photo CHICAGO (Reuters) -U.S. Health Secretary Robert F. Kennedy Jr.'s dismissal of an independent panel of experts citing the goal of restoring trust in vaccines could undermine confidence in those available now, putting Americans at risk of preventable infectious diseases, public health experts and others said on Monday. Kennedy, a longtime vaccine skeptic, said in a commentary published in the Wall Street Journal that he was firing all 17 members of the Advisory Committee for Immunization Practices (ACIP) at the Centers for Disease Control and Prevention "to re-establish public confidence in vaccine science.' The committee reviews vaccines approved by the U.S. Food and Drug Administration and makes recommendations to the CDC on their use. "I fear that there will be human lives lost here because of this," said Dr. Sean O'Leary, chair of the American Academy of Pediatrics' Committee on Infectious Diseases. "It is a special kind of irony that he is saying he is doing this to restore trust, given that he is, as an individual, more responsible for sowing distrust in vaccines than almost anyone I can name," O'Leary said. O'Leary said pediatricians have already been fielding calls from parents who are confused about conflicting announcements earlier this month narrowing the use of COVID-19 vaccines for healthy children and pregnant women. "This is only going to add to that," he said. A U.S. Department of Health and Human Services spokesman said the agency is prioritizing public health, evidence-based medicine, and restoring public confidence in vaccine science. The firing of the entire vaccine advisory committee comes just weeks before a scheduled public meeting in which advisers were expected to weigh in and vote on a number of decisions, including the 2025-26 COVID-19 vaccine boosters. The health agency said the committee will meet as scheduled on June 25-27, but it is unclear who would serve on that panel or how they have been vetted for conflicts of interest. The agency said it would replace them with new members currently under consideration. Fired ACIP member Noel Brewer, a professor of public health at the University of North Carolina, said it took about 18 months from the time he applied until he was serving as an ACIP member. Senate Minority Leader Chuck Schumer decried the changes. "Wiping out an entire panel of vaccine experts doesn't build trust — it shatters it, and worse, it sends a chilling message: that ideology matters more than evidence, and politics more than public health," he said in a statement. Former CDC Director Dr. Thomas Frieden called out Kennedy's "false claims" in the Wall Street Journal piece, saying the panel was rife with conflicts of interest. Most of the panel was appointed last year, the CDC website shows. "Make no mistake: PoliticizingtheACIPas Secretary Kennedy is doingwill undermine public trust under the guise of improving it." (Reporting by Julie Steenhuysen in Chicago; additional reporting by Mike Erman in New York; editing by Caroline Humer and Stephen Coates)


The Star
6 hours ago
- The Star
COVID-19 virus protein triggers immune attack on healthy cells: study
JERUSALEM, June 10 (Xinhua) -- Israeli researchers have discovered that a protein from the SARS-CoV-2 virus, responsible for COVID-19, can cause the immune system to attack healthy cells mistakenly, the Hebrew University of Jerusalem said in a statement on Tuesday. The study, published in Cell Reports, sheds light on how severe COVID-19 complications may occur and suggests new ways to prevent immune-driven damage from the virus. The researchers found that the virus's nucleocapsid protein (NP), which normally helps package the virus's genetic material inside infected cells, can spread to nearby uninfected epithelial cells. Once on the surface of these healthy cells, NP would be mistakenly identified by the immune system as a threat. The immune system then deploys anti-NP antibodies, which mark these uninfected cells for destruction. The process triggers the classical complement pathway, a part of the immune response that leads to inflammation and tissue damage, contributing to severe COVID-19 symptoms and possibly long COVID. Using lab-grown cells, advanced imaging, and samples from COVID-19 patients, the researchers found that NP binds to a type of molecule on cell surfaces. The binding causes the protein to cluster on healthy cells, further confusing the immune system. The study also found that the drug enoxaparin, a common blood thinner and heparin analog, blocks NP from sticking to healthy cells. In both lab tests and patient samples, enoxaparin helped prevent immune attacks by occupying the binding sites that NP uses. According to the researchers, the discovery may offer new hope for reducing immune-related complications in COVID-19 and potentially other viral infections.


The Star
17 hours ago
- The Star
Extend reinstatement application period, says MP to insurers
PETALING JAYA: Major insurance companies should extend the reinstatement application period by 60 more days, says Bayan Baru MP Sim Tze Tzin. He said in a statement on Tuesday (June 10) that this interim measure should be extended so that more people who have had to terminate their medical insurance have sufficient time to reactivate it. Sim then added that the reinstatement period to facilitate recovery will end on June 30 and said that since Bank Negara introduced the interim measure, one positive development is the increase in people reactivating their policies. 'This period is crucial. Lapsed policies may still be reinstated without adversely affecting existing coverage, but action must be taken before the deadline,' he added. Sim then said that he urged those who have terminated their policies due to financial pressure or premium increases to contact their respective insurance companies to check their cases for possible policy recovery. 'I also urge insurance agents and Malaysians to share this important information with friends and family. Do not wait until it's too late,' he said. Sim then said NAMLIFA Central Region had shared a true story about a 'Mr Ravi' who took out an insurance policy in 2014 when he was 27-years-old. He said that in this instance, the comprehensive coverage initially cost RM200 per month but rose to RM273.24 by 2023 due to two premium increases. Sim added that this policyholder struggled after losing his job during the Covid-19 pandemic and could not maintain payments. 'This financial strain led to him cancelling his policy in late 2024, leaving him uninsured when he had a stroke,' said Sim 'Fortunately, Bank Negara Malaysia's interim measure allowed him to reactivate his policy without undergoing underwriting, enabling him to claim for treatment, though many remain unaware of this opportunity,' he added.